# US 2026/0242355 A1 · Pai-1 inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242355 A1
- Document ID: US20260242355A1
- Status: Published application
- Kind: A1
- Application number: 19/309,326
- Filed: 2025-08-25
- Published: 2026-08-20
- Earliest claimed: 2025-02-18
- Assignees: The Cleveland Clinic Foundation
- Applicants: The Cleveland Clinic Foundation
- Inventors: Vara Prasad Josyula; Thaddeus Stappenbeck
- Web page: https://patentgrep.com/patent/US20260242355A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4245: Oxadiazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07D 213/80: in position 3
- C07D 215/12: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/40: Acylated on said nitrogen atom
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 319/16: condensed with one six-membered ring
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/10: linked by a carbon chain containing aromatic rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting PAI-1 using the compounds, and methods of treating IBDs using the compounds.

## Claims

### Claim 1

A compound of formula (Ia):
or a pharmaceutically acceptable salt thereof, wherein:
R2 is H, halo, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy;
R3 is H, halo, or C1-C4 alkyl;
wherein R2 and R3 are optionally taken together with the carbon atoms to which they are attached to form a 5- or 6-membered ring optionally substituted with 1 or 2 substituents independently selected from C1-C4 alkyl, halo, and oxo;
X6 is CR6 or N;
R6 is H, halo, or C1-C4 alkyl; and
R8 is a group of formula:
wherein Rx is —(CH2)n—Y or a monocyclic heterocyclyl having 1 or 2 heteroatoms independently selected from O and N, wherein the monocyclic heterocyclyl is unsubstituted or substituted with 1 C1-C4 alkyl group; wherein n is 1 or 2, and Y is selected from —COORg and —NRhRi, wherein Rg, Rh, and Ri are each independently selected from H and C1-C4 alkyl.

### Claim at position 2

-4. (canceled)

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R2 is H, halo, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy; and
R3 is H, halo, or C1-C4 alkyl.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are taken together with the carbon atoms to which they are attached to form a phenyl ring, a 5- or 6-membered heterocyclyl ring having 1 or 2 oxygen atoms, or a 5- or 6-membered heteroaryl ring having 1 or 2 nitrogen atoms, each of which is independently unsubstituted or substituted with 1 C1-C4 alkyl group.

### Claim at position 5

-10. (canceled)

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X6 is CR6 and R6 is H.

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X6 is N.

### Claim at position 8

-17. (canceled)

### Claim 18 (depends on 1)

The compound of claim 1, wherein the compound is selected from:
4-chloro-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid,
2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-chloro-benzoic acid,
2-[[3-(1-tetrahydropyran-4-ylpyrazol-3-yl)benzoyl]amino]benzoic acid,
2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]benzoic acid,
2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]benzoic acid,
2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]benzoic acid,
4-methyl-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid,
2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-methyl-benzoic acid,
4-methyl-2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]benzoic acid,
2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]-4-methyl-benzoic acid,
2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-4-(trifluoromethyl)benzoic acid,
2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-(trifluoromethyl)benzoic acid,
2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]-4-(trifluoromethyl)benzoic acid,
2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]-4-(trifluoromethyl)benzoic acid,
4-isopropyl-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid,
2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-isopropyl-benzoic acid,
4-isopropyl-2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]benzoic acid,
2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]-4-isopropyl-benzoic acid,
4-tert-butyl-2-[[3-(1-tetrahydropyran-4-ylpyrazol-3-yl)benzoyl]amino]benzoic acid,
4-tert-butyl-2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]benzoic acid,
4-tert-butyl-2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]benzoic acid,
4-tert-butyl-2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]benzoic acid,
4-methoxy-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid,
2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-methoxy-benzoic acid,
4-methoxy-2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]benzoic acid,
2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]-4-methoxy-benzoic acid,
2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-4-(trifluoromethoxy)benzoic acid,
2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4-(trifluoromethoxy)benzoic acid,
2-[[4-(1-tetrahydropyran-4-ylpyrazol-4-yl)pyridine-2-carbonyl]amino]-4-(trifluoromethoxy)benzoic acid,
2-[[4-[1-(2-carboxyethyl)pyrazol-4-yl]pyridine-2-carbonyl]amino]-4-(trifluoromethoxy)benzoic acid,
4,5-dichloro-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid,
2-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-4,5-dichloro-benzoic acid,
3-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]naphthalene-2-carboxylic acid,
3-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]naphthalene-2-carboxylic acid,
6-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-2,3-dihydro-1,4-benzodioxine-7-carboxylic acid,
[6-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-2,3-dihydro-1,4-benzodioxine-7-carbonyl]oxysodium,
6-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-2,3-dihydro-1,4-benzodioxine-7-carboxylic acid,
6-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-1,3-benzodioxole-5-carboxylic acid,
5-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]-1H-indazole-6-carboxylic acid,
1-methyl-5-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]indazole-6-carboxylic acid,
5-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-1H-indazole-6-carboxylic acid,
5-[[3-[1-(2-carboxyethyl)pyrazol-4-yl]benzoyl]amino]-1-methyl-indazole-6-carboxylic acid,
2-[[3-[1-[2-(dimethylamino)ethyl]pyrazol-4-yl]benzoyl]amino]benzoic acid,
2-[[3-[1-(4-piperidyl)pyrazol-4-yl]benzoyl]amino]benzoic acid,
2-[[3-[1-(1-methyl-4-piperidyl)pyrazol-4-yl]benzoyl]amino]benzoic acid,
sodium 4,5-dichloro-2-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)picolinamido)benzoate, and
sodium 7-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)picolinamido)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate,
and pharmaceutically acceptable salts thereof.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method of treating an inflammatory bowel disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 18)

A pharmaceutical composition comprising a compound of claim 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 22

A compound:
4-chloro-2-[[3-(1-tetrahydropyran-4-ylpyrazol-4-yl)benzoyl]amino]benzoic acid, or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

A pharmaceutical composition comprising the compound of claim 22, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
